Moderna Just Gave Investors Yet Another Thing to Cheer About

Moderna (MRNA) just delivered a profit when analysts expected a loss. The company posted $0.38 EPS on $1.31B in revenue, up 29% year over year, and raised full-year guidance.

The balance sheet adds support. MRNA ended the quarter with $8.1-8.3B in cash.

The second catalyst came from the pipeline. MRNA's cancer vaccine, developed with Merck (MRK), showed strong Phase 3 results, cutting melanoma recurrence risk by 42%. The partnership ties MRK to the same readout, though the source quantifies the benefit only for the trial result itself.

The stock has surged 720% in 2026. That run is the central tension for traders. Interpretation: after a move that size, a profitable beat and a positive Phase 3 print may already be reflected in the price, leaving less room for upside surprise. The source flags the same concern, noting that significant optimism is already priced in.

The other stated risk is COVID vaccine sales volatility. Interpretation: because the profit was a surprise, the durability of that revenue base matters as much as the beat itself.